Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma 44Breast Neoplasms 26Sarcoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Burkitt Lymphoma 14Neuroblastoma 13Hodgkin Disease 13Leukemia 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 8Wilms Tumor 7Sarcoma, Synovial 7Neurofibrosarcoma 7Leiomyosarcoma 7Histiocytoma, Malignant Fibrous 7Hemangiosarcoma 7Fibrosarcoma 7Endometrial Neoplasms 7Urinary Bladder Neoplasms 6Multiple Myeloma 6Malignant mesenchymal tumor 6Liposarcoma 6Rhabdomyosarcoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Kidney Neoplasms 5Hemangiopericytoma, Malignant 5Waldenstrom Macroglobulinemia 4Sarcoma, Alveolar Soft Part 4

Interventions

Trastuzumab 1Paclitaxel 1Lapatinib 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Invasive Breast Cancer × Doxorubicin × Clear all
NCT00486668 2016-06-06

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

NSABP Foundation Inc

Phase 3 Unknown
529 enrolled
Breast

Invasive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡